FDA Approves Enspryng for Thyroid Eye Disease, Given at Home
Topics: Pipelines & Trials, Today's News
Jeff's Daily Pick. The FDA approved Genentech's Enspryng (satralizumab) for thyroid eye disease, the first treatment for it that patients can inject at home. In the SatraGO-2 trial, 52.9% had less eye bulging at week 24 versus 23.4% on placebo. SatraGO-1 missed its main goal.
In the United States, the Food and Drug Administration approved Enspryng (satralizumab-mwge) on October 15, 2026 for adults with thyroid eye disease (TED), Genentech announced. It is the first subcutaneous treatment for TED that a patient or caregiver can give at home after training, and the first IL-6 receptor blocker approved for the disease.
The disease
TED, also called Graves' ophthalmopathy, is an autoimmune disease of the tissue around the eyes. It causes redness, swelling, eyelid retraction, bulging eyes (proptosis), double vision (diplopia) and pain, and it can threaten sight. Genentech puts it at about 155 people per 100,000. It occurs most often with hyperthyroidism, and about half of those patients have at least mild TED.
Two trials, two results
SatraGO-1 and SatraGO-2 were identically designed Phase 3 trials against placebo, with 258 patients in total from 19 countries. The primary endpoint was the share of patients with active, moderate to severe TED whose proptosis fell by at least 2 mm in the study eye at week 24. SatraGO-1 missed that endpoint. SatraGO-2 met it: 52.9% responded on Enspryng versus 23.4% on placebo, a gap of 29.5 points. Double vision improved in 60.7% versus 25.8%.
Genentech says SatraGO-2 gave consistent results in its overall population, active and chronic disease combined, and that no new safety signals appeared compared with the drug's known profile in neuromyelitis optica spectrum disorder (NMOSD). After the first doses, the injection is given every four weeks.
What it shows / what it doesn't
- Shows: in one Phase 3 trial, more than twice as many patients had a meaningful reduction in eye bulging on the drug as on placebo.
- Doesn't show: a consistent result across both trials. SatraGO-1 missed its primary endpoint, and the release gives no numbers for it.
- Doesn't show: how the drug compares with the infusion treatment already on the market. No head to head trial is cited.
- Status: FDA approval after priority review. Full trial results were presented at the ASOPRS Fall Scientific Symposium in October 2025.
Enspryng was first approved in 2020 for NMOSD; thyroid eye disease is its second US indication. The first drug approved for TED, teprotumumab (Tepezza), cleared the FDA in January 2020 and is given by intravenous infusion, which is the burden Genentech is pitching against.
Sources
Regulatory decision (FDA) announced in a company press release; Phase 3 results presented at a meetingGenentech. FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED). Press release, October 15, 2026. gene.com
Roche. FDA approves Roche's Enspryng for thyroid eye disease. Media release, October 16, 2026. roche.com
U.S. Food and Drug Administration. FDA approves first treatment for thyroid eye disease. January 21, 2020. fda.gov
U.S. Food and Drug Administration. Tepezza (teprotumumab-trbw) prescribing information, for intravenous use, initial U.S. approval 2020. accessdata.fda.gov
Get Facts First, every Sunday
One email a week: the 5 facts that mattered in U.S. and French politics, the economy, AI and health, each checked against the original source. No spam. Unsubscribe in one click.
By subscribing you agree to receive the newsletter. See the privacy policy.